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Abstract: The injectable hydrogel with desirable biocompatibility and tunable 
properties can improve the efficacy of stem cell-based therapy. However, the 
development of injectable hydrogel remains a great challenge due to the restriction of 
crosslinking efficiency, mechanical properties, and potential toxicity. Here, we report 
that a new injectable hydrogel system were fabricated from hyperbranched 
multi-acrylated poly(ethylene glycol) macromers (HP-PEGs) and thiolated hyaluronic 
acid (HA-SH) and used as a stem cell delivery and retention platform. The new 
HP-PEGs were synthesized via in situ reversible addition fragmentation chain transfer 
(RAFT) polymerization using an FDA approved anti-alcoholic drug - Disulfiram (DS) 
as the RAFT agent precursor. HP-PEGs can form injectable hydrogels with HA-SH 
rapidly via thiol-ene click reaction under physiological conditions. The hydrogels 
exhibited stable mechanical properties, non-swelling and anti-fouling properties. 
Hydrogels encapsulating adipose-derived stem cells (ADSCs) have demonstrated 
promising regenerative capabilities such as the maintenance of ADSCs’ stemness and 
secretion abilities. The ADSCs embedded hydrogels were tested on the treatment of 
diabetic wound in a diabetic murine animal model, showing enhanced wound healing.  
1. Introduction 
Diabetic wounds are a severe complication of diabetes that aggravates the patient’s 
condition, and affects a dramatically increasing population.[1] In view of the specific 
pathophysiological abnormalities of the wound environment including prolonged 
inflammation, vascular problems, inhibited re-epithelialization, a major failure has 
been seen with single treatment or FDA approved therapy devices.[2] Therefore, a 
combined therapeutic approach using advanced technologies that alleviates the 
deleterious pathological factors is of great interest. There is a great promise for stem 
cell-based treatment for diabetic wounds that has been reported over the past decade.[3] 
However, the hostile wound environment minimizes the retention and survival of stem 
cells, which significantly limits the clinical translation of stem cell therapy. To 
maintain and protect the stem cells that have been delivered onto the harsh diabetic 
environment, hydrogel systems have been explored to improve the engraftment of 
transplanted stem cells for diabetic wound repair.[4] Among them, in situ formed 
injectable hydrogel system has attracted much attention for wound healing application 
in recent years.[5–7] The injectable hydrogel can be easily applied on any irregular 
shape during hydrogel formation without using the complex mould,[8–10] and possess 
the advantages of easy administration, efficient cell encapsulation, minimal invasion, 
and enhanced patient compliance,[11] making them attractive for various biomedical 
applications. The components of injectable hydrogels range from natural (e.g. 
hyaluronic acid, chitosan, alginate, collagen, gelatin) to synthetic (e.g. poly(ethylene 
glycol), polyacrylamide, Poly(Lactide-co-Glycolide)) materials.[4] Naturally derived 
hydrogels have been frequently used in tissue engineering, as the components have the 
same or similar properties to the natural extracellular matrix (ECM).[12] However, 
these naturally derived biomaterials always show large heterogeneity in structure, poor 
stability and mechanical performance as well as relatively high cost.[13] Synthetic 
hydrogels are appealing for tissue engineering and regeneration as their properties are 
tunable, reproducible, and much easier to pre-design in order to meet numerous of 
specific requirements.[12] Although there have been various synthetic injectable 
hydrogels reported for wound healing application, a majority of the reported hydrogels 
suffer from potential toxicity, less biological cues and unsuitable mechanical 
properties, etc. which prevent the successful clinical translation of synthetic 
hydrogels.[14,15] Therefore, a well-designed in situ formed injectable hydrogel system 
that combines a well-constructed synthetic polymer with a properly selected naturally 
derived biopolymer could be an appropriate consideration to create improved materials 
to achieve an effective healing process.  
Among numerous synthetic biomaterials, poly(ethylene glycol) (PEG) and its 
derivatives have been extensively used for fabrication of biocompatible hydrogels for 
cell culture scaffolds[16] and tissue engineering.[17] However, the conventional 
linear and/or multi-armed star PEG (4-armed or 8-armed) based materials are 
suffering from their low functional group density, which largely restricts their reaction 
efficiency. One solution is to construct PEG materials with highly branched structures. 
As one of the classical approaches to synthesize branched polymers, ‘Strathclyde 
route’ is using free radical polymerization of mono-vinyl monomers with a small 
amount of divinyl crosslinkers.[18] However, the polymers produced by such an 
approach still possess limited pendent vinyl groups, which make them not ideal 
candidates as the crosslinkers to form injectable hydrogels. To overcome this 
drawback, Wang et al. proposed a kinetically controlled strategy to polymerize the 
multi-vinyl monomers.[19–24] PEG based hyperbranched polymers with high 
branching degree and pendent vinyl density were successfully achieved.[25–28] The 
high content of pendent vinyl groups endows them the ability to generate in situ 
injectable hydrogel systems rapidly. However, there is still one significant limitation 
on the previous studies which used atom transfer radical polymerization (ATRP) 
requiring potential toxic copper catalysts.  
To address this issue, reversible addition fragmentation chain transfer (RAFT) 
polymerization has been used to synthesize PEG polymers without using toxic metal 
catalysts.[6,29] While, the most significant challenges in RAFT polymerization are 
the complicated synthesis procedure for RAFT agents, which needs to use noxious 
and toxic organic reagents (carbon disulfide or iodine), and the subsequent 
time-consuming reaction and purification steps.[30,31] Wang et al. explored one-pot 
in situ RAFT polymerization of PEG-based monomethacrylate and dimethacrylate 
monomers by using bis(thiobenzoyl) disulfide as a precursor of RAFT agent and a 
well-controlled polymerization was obtained.[32] Inspired by this work, another 
chemical disulfiram (DS or tetraethylthiuram disulfide, as shown in Figure 1), was 
hypothesized that it can potentially be utilized to perform the in situ RAFT 
polymerization. This was successfully verified in our recent work, where a 
DS-poly(ethylene glycol) methyl ether acrylate (DS-PEGMEA) was synthesized via 
RAFT polymerization utilizing DS as the RAFT precursor.[33] One advantage of 
using DS as the RAFT agent precursor is the relatively low cost compared with 
conventional RAFT agent. Moreover, another important advantage is that the DS is an 
FDA approved anti-alcoholic drug (ANDA # 086889), which has been widely used in 
clinical applications for more than 60 years, and recently also been explored and 
reported as an effective anti-cancer drug.[34–38] We believe that DS, a commercially 
available, low cost, biocompatible, and FDA approved chemical, is very appealing for 
the preparation of well-defined biomaterials via in situ RAFT polymerization.  
In this paper, we report a new generation of in situ formed injectable hydrogel system 
fabricated by a series of newly designed hyperbranched PEG macromers (HP-PEGs) 
in combination with thiolated hyaluronic acid (HA-SH). The HP-PEGs with 
numerous pendent acrylate groups were synthesized by an in situ RAFT 
polymerization of PEGDA using Disulfiram (DS) as a RAFT agent precursor. HA-SH 
was used to crosslink with the HP-PEGs to generate injectable hydrogels via thiol-ene 
click reaction. The gelation time, mechanical properties, swelling and degradation 
profile, and antifouling property were studied in detail. Furthermore, the behaviours 
of adipose-derived stem cells (ADSCs) encapsulated in the hydrogel were evaluated. 
The efficacy of the HP-PEG/HA-SH/ADSC system for the treatment of diabetic 
wound healing was assessed on a humanized excisional diabetic wound model in rats.  
2. Materials and Methods 
2.1 Differentiation test for ADSCs encapsulated in the HP-PEG1/HA-SH hydrogel 
Immunofluorescence for Oct4, Sox2, and Nanog for ADSCs was carried out to detect the 
undifferentiated status. HP-PEG/HA-SH/ADSCs was first fixed with 4% paraformaldehyde, and 
then reacted with antibodies against Oct4, Sox2, and Nanog. After washed with PBS/Triton X-100, 
the hydrogel reacted with corresponding secondary antibodies, and counterstained with DAPI. 
Immunofluorescence was observed with a fluorescence microscope.  
For in vitro differentiation assessment, ADSCs were induced by relative induction media and media 
without growth factors, separately.  
Adipogenic induction medium: Preadipocyte basal medium-2 supplemented with 16.6% FBS, 50 
μg mL-1 ascorbate-2 phosphate, 10-7 M dexamethasone, 50 μM indomethacin, 0.45 mM 
3-isobutyl-1-methyl-xanthine and 10 μg mL-1 insulin.  
Chondrogenic induction medium: add ITS + (Gibco-BRL) and 10 ng mL-1 TGF-1 (Preprotech, 
Rocky Hill, NJ) into MSC differentiation medium - chondrogenic (PT3925). 
Osteogenic induction medium: MSC differentiation medium-osteogenic (PT3924) supplemented 
with 16.6% FBS, 50 μg mL-1 ascorbate-2 phosphate), 10-8 M dexamethasone and 10 mM 
-glycerophosphate.  
After separate induction, ADSCs were stained by oil red O, Alizarin red, and safranin-O to detect 
the morphology.  
2.2 Growth factors secretion of ADSCs encapsulated in the HP-PEG1/HA-SH 
hydrogel 
Conditioned media was collected from ADSCs seeded in the hydrogels or plated in wells after 1, 4, 
and 7 days incubation. Angiogenic protein levels of PIGF, VEGF, and TGF-β were quantified using 
multi-plex ELISA system (Sigma).  
2.3 Animals 
6-8-week old male Sprague Dawley (SD) rats with body weights range between 180-240 g were 
used for subcutaneous hydrogel implantation, and inducing diabetic rat model. Rats were fed ad 
libitum water and rodent diet, and housed in the Animal Experimentation of the Chinese Academy 
of Medical Sciences and Peking Union Medical College Institute of Biomedical 
Engineering-approved animal care guidelines. All procedures were approved by the Chinese 
Academy of Medical Sciences and Peking Union Medical College Institute of Biomedical 
Engineering. 
2.4 In vivo biosafety and degradation profile of HP-PEGs/HA-SH hydrogels in a 
subcutaneous implantation model 
A subcutaneous implantation was used to test the in vivo biosafety and biodegradation of the 
injectable HP-PEG1/HA-SH (5% w/v) and HP-PEG2/HA-SH hydrogel (5% w/v). After anesthesia 
with an intraperitoneal injection of 8% chloral hydrate, four incisions with 1 cm full-thickness 
transverse each were made on both sides of the shaved dorsum of SD rats. Prepared hydrogels (100 
μL) were implanted subcutaneously and incisions were closed with 5-0 nylon suture (Ethicon, 
Somerville, NJ) and covered with a sterile occlusive dressing (Tegaderm; 3M, St. Paul, MN). 
Wounds were examined every other day and hydrogels were harvested at 3, 7, 11, 14, and 21 days 
post-wounding. Residual hydrogel was taken and weighted (4 samples for each condition).  
2.5 Diabetic animal model 
In order to generate diabetic animals, STZ was used to chemically induce healthy SD rats to develop 
type 1 diabetes via cauda vein injection (45 mg kg-1 of STZ dissolved in a 0.1 M sodium citrate 
buffer). Diabetes was verified by serum glucose levels after the injection. Serum glucose level > 
16.7 mmol L-1 for at least 4 weeks was defined as successfully developed diabetic rat model. The 
serum glucose levels were tested pre- and post-injection, and every 7 days during the experiments 
with a blood glucose meter (OneTouch Ultra® Blood Glucose Monitoring System).  
2.6 Humanized diabetic wound model and treatment groups 
To better mimic the human wound healing process, a splinted excisional wound model was utilized 
to prevent wound contraction and allow wound healing through re-epithelialization and granulation 
tissue formation. Briefly, after full thickness excisional skin wound of 1.1 cm diameter circle was 
created on the dorsum, wound was circumscribed by silicone rings sutured onto the skin surface 
surrounding the excision area with 5-0 nylon. Four wounds were generated on each animal. Animals 
were randomized into the following five treatment groups: directly local injection of ADSCs, S&N 
(INTRASITE◊GEL, a commercially available product from Smith & Nephew), injectable 
HP-PEG/HA-SH hydrogel, injectable HP-PEG/HA-SH/ADSCs hydrogel, and blank (no treatment) 
group (n = 16 wounds per treatment group). For the direct ADSCs local injection group, 200 μL (2.5 
× 106 cell mL-1) cell suspension was injected subcutaneously around the wound edge. For the 
injectable hydrogel with (concentration of ADSCs in the hydrogel: 2.5 × 106 cell mL-1) or without 
ADSCs groups, 200 μL solution was injected directly onto the wound surface. 
Digital images were taken at scheduled time points (days 0, 11, 21 post-procedure). The wound area 
was measured by two blinded evaluators via Image J software (n = 8 wounds for each condition). 
Wound closure rate (%) was defined as: (origin wound area - residual wound area at day ‘X’) / 
origin wound area × 100%.  
2.7 Histological analysis 
At scheduled time points, wound tissues were excised and immediately fixed in 4% 
formaldehyde/PBS solution overnight. Samples were then dehydrated with a graded series of 
ethanol and embedded in paraffin. Tissues were then sectioned into slices with a thickness of 5 μm 
and stained by hematoxylin and eosin (H&E, Sigma-Aldrich), and Masson’s trichrome 
(Sigma-Aldrich) and visualized by an optical microscope.  
Masson’s trichrome stained sections were utilized to measure the newly formed dermis thickness, 
using the Image J software (n = 8 wounds for each condition) with a minimum of 6 measurements 
per sample. Percentage of neo-dermis thickness (%) was calculated as (neo-dermis thickness / the 
surrounded normal dermis thickness) × 100%.  
2.8 Immunohistochemistry and immunofluorescence 
For the immunohistochemical staining, 5 μm thickness paraffin sections were deparaffinized, 
washed three times in PBS for 5 min. Then the sections were blocked with 5% serum for 30 min. 
Next, the slides were incubated in primary antibodies, anti-Keratin 10 (1:300), CD31 (1:200), 
α-SMA (1:25), VEGF (1:50), CD11b (1:100), TNF-α (1:200), and IL-1β (1:200). All tissues were 
imaged at 400 ×, five high power microscopic fields for each separate wound sample by three 
blinded evaluators. The inflammation response was identified by the expression of inflammatory 
cytokines which was quantified by the positively stained cells. Vascularization was evaluated by 
counting CD31-positive and α-SMA positive staining cells. Re-epithelialization rate was defined as: 
(the length of newly formed epidermis of both sides /original wound length) × 100%.  
Immunofluorescence was also performed after sections’ fixation in aceton at -20 oC. TNF-α, CD31, 
and α-SMA antibodies were used to perform the immunofluorescent staining. Nuclei were stained 
with DAPI (purchased from Abcam Inc.). Immunofluorescence images were acquired with an 
AxioCam HRm camera mounted on a Zeiss Imager M2 microscope.  
2.9 Statistical analysis  
All values are expressed as mean ± standard deviation (SD). Statistical differences between two 
groups were determined using the student’s unpaired t test. A p value < 0.05 was considered 
statistically significant. 
3. Results and discussion 
3.1 Multifunctional HP-PEG polymer synthesis 
In order to explore the optimal reaction condition of in situ RAFT polymerization, six 
batches of polymerizations were carried out as shown in Supplementary table 1. 
Firstly, two reactions as controls were carried out without the use of 
2,2’-Azobis(2-methylpropionitrile) (AIBN) (Entry 1) or DS (Entry 2), respectively. 
Entry 1 showed no sign for the occurrence of polymerization as no polymer peak was 
detected by GPC even after 24 h, while Entry 2 formed a crosslinked network rapidly 
within 15 min indicating an uncontrollable reaction behaviour. Then, two ratios (1:2 
and 1:1.4) of DS to AIBN as well as different reaction temperatures were evaluated 
for the in situ RAFT polymerization of PEGDA (Entry 3-6). As shown in Figure 
2A-2D, the polymer mixtures are still soluble even when the monomer conversion 
was up to 60% for all the four systems, demonstrating the critical roles of DS in the 
reaction to in situ form the RAFT agents. Such high monomer conversion is 
unexpected given the Flory-Stockmayer theory predicted that such system will be 
gelled at low monomer conversion. Similar results were also reported in our previous 
work [6,19,21–23] and attributed to the kinetic control over the chain growth, 
inter-/intra- molecular crosslinking. Moreover, polymerization process shows a 
two-stage growth behaviour. At the early stage (monomer conversion less than 40%), 
Mw increased with monomer conversion in a linear manner and the GPC traces 
(Figure S1) showed single peaks with a low PDI. While in the later stage, the Mw 
increased rapidly and GPC peaks showed a multiple peaks with a high PDI, indicating 
the occurrence of the intermolecular crosslinking, combination of the polymer chains 
in the reaction system. [22,23] 
The reaction kinetic was studied by varying the AIBN/DS ratio and temperature. As 
shown in Figure 2E, more AIBN feeding results in a much faster polymerization rate 
and a higher PDI at the same conversion. Thus, the feeding ratio of 1:1.4 (molar ratio 
of DS: I) was selected to delay the later stage of polymerization compared with the 
feeding ratio of 1:2. Similarly, the optimized reaction temperature is selected at 70 oC.  
The samples taken from Entry 4 were purified, and the polymer structure was 
characterized in detail. HP-PEGs with molecular weights of 10 and 20 kDa (termed as 
HP-PEG1 and HP-PEG2, respectively) were obtained. From the GPC results, the value 
of Mark-Houwink exponent (α) is 0.29 for HP-PEG1 and 0.30 for HP-PEG2, 
respectively (Figure S2), lower than characteristic α of a linear structure (more than 
0.5), indicating a sphere-shaped morphology, suggesting the formation of branched 
structure. 1H-NMR results show the existence of the acrylate moieties in the purified 
HP-PEG1 and HP-PEG2 (Figure 2 and Figure S4). Based on the comparison of the 
amount of pendent unit with the amount of entire monomer repeating units, the branch 
ratios were calculated, which showed values of approximately 32% and 45% (Figure 
S3), respectively. We can also observe from the 1H-NMR spectrum of a purified 
HP-PEG1 polymer that the peaks of DS and AIBN moieties can be found within the 
polymer chains, which reveals that the polymerization follows the proposed in situ 
RAFT polymerization (Figure 2F).  
3.2 Injectable HP-PEG/HA-SH hydrogels 
PEG/HA hydrogels have been studied in the field of tissue engineering for years. Shea 
et al. designed a PEG/HA hydrogel by photopolymerization and used as a non-viral 
gene delivery vector;[39] Webb et al. developed a semi-interpenetrating PEG/HA 
hydrogel to support 3D cell culture for cell therapy applications.[40] These PEG 
macromers are suffered from low functional group density, resulting in a 
compromised crosslinking degree; besides, the crosslinker synthetic pathways are 
complicated. Thus, we utilized our HP-PEGs to crosslink with HA-SH to fabricate in 
situ formed hydrogels via Michael addition reaction. HA-SH is a widely used 
derivative of HA, which possesses the biological and regenerative properties of HA, 
and also can crosslink with acrylate groups spontaneously via Michael addition under 
physiological conditions. As expected, rapid gelation occurs when the acrylate groups 
from the polymer reacting with the thiol groups from the HA-SH. The hydrogels are 
transparent and easy to be handled. Gelation time of both HP-PEG/HA-SH hydrogels 
was examined using the stirring method. Both hydrogels exhibit fast gelation time at 
various concentrations (2.5%, 5%, and 10% w/v) and the higher concentration showed 
faster gelation rate (Figure 3A). For example, the gelation time is about 96 seconds 
for 2.5% (w/v) HP-PEG1 polymer versus 57 seconds for 10% (w/v) polymer 
HP-PEG1. The rapid gelation demonstrated the suitability as injectable hydrogels, 
which has potential to address current needs for clinical use of biomaterials.[41,42] By 
adjusting the pendent acrylate content and polymer concentration, the gelation time 
can be adjusted to meet the needs of a specific tissue engineering application.  
To reveal the mechanical properties of HP-PEG/HA-SH hydrogels, rheological 
measurements were performed during the gelation process sequentially using time and 
frequency sweep (Figure 3B and Figure S5). Typically, at the concentration of 5%, 
HP-PEG1/HA-SH exhibit approximate 136 Pa of storage modulus which is within the 
range of storage modulus of soft tissue (Figure 3C). Both hydrogels showed low 
frequency dependence (Figure S6 and Figure S7) for all concentrations, 
demonstrating that the hydrogels are highly elastic.[7] Proper mechanical properties 
can support the encapsulated cells with a favorable environment as well as no extra 
burden to the host tissues.  
To study the hydrogel swelling and degradation properties in vitro, the hydrogel 
samples (5% (w/v)) were incubated in PBS buffer at 37 oC. After the hydrogels 
reached their equilibrium swelling levels within 1 day, their wet weight remained 
almost constant for 4 days. The hydrogels then showed slight swelling within 40 days 
(1.9-time of original weight) (Figure 3D). The hydrogels underwent remarkable 
swelling and became shapeless after 40 days. The hydrogel structure started to break 
and finally disappeared after it reached the maximum water retention ability. Thus, we 
successfully obtained a non-swelling hydrogel system, which avoids the limitations of 
weak mechanical toughness caused by swelling. This kind of non-swelling profile, in a 
relatively long time period, will result in less medical complications caused by high 
hydrogel swelling ratios, which is a desirable advantage of hydrogels being applied 
onto wound sites.  
To investigate the porosity and morphology of the hydrogel, SEM were used to 
capture the microstructure. The HP-PEG/HA-SH hydrogels show a microporous 
sponge-like structure with the pore size ranging from 5 to 20 μm (Figure S8).  
We also tested the antifouling property of our hydrogel systems, because the PEG 
derivatives have been proved to be an antifouling biomedical material due to its 
biocompatibility and hydrophilicity. The HP-PEG1/HA-SH hydrogel exhibits a 
relatively lower amount of protein adsorption than the collagen/chitosan hydrogel and 
HP-PEG1 hydrogel (formed by UV curing) from 2 to 24 h incubation period with FBS 
solution (Figure 3E). The well-maintained antifouling property endows the hydrogel 
with the ability to mitigate the effects of the foreign body response after implantation.  
In view of the suitable mechanical stability, the injectable profile, and the non-swelling 
and antifouling properties, we believe this hydrogel system to have chemical 
advantages and potential satisfaction for both medical specialists and patients, 
providing it with great superiority as an alternative biomaterial for wound healing.  
3.3 Biocompatibility of HP-PEG/HA-SH hydrogels 
To determine the biocompatibility of HP-PEG polymers and HP-PEG/HA-SH 
hydrogels, 3T3 and ADSCs were used for in vitro cell viability tests by alamarBlue 
assay. Both cell lines showed high cell viability when cocultured with different 
polymer concentrations (Figure S9). The cytotoxicity test for the hydrogels were 
conducted by seeding the cells into the HP-PEG/HA-SH hydrogels and evaluated by 
alamarBlue assay. Both hydrogels exhibited high cell viability for both cell lines 
(Figure S10), indicating that this in situ hydrogel system did not show toxicity on the 
cells. We also performed in vivo biosafety and degradation test of both hydrogels. After 
implantation, no signs of infection, inflammation or rejection were detected. The 
hydrogels exhibited minimal swelling and a slow degradation rate within 21 days 
(Figure S11). In the current study, we selected HP-PEG1/HA-SH hydrogel with 5% 
(w/v) exhibiting 68 seconds of gelation time, and 125 Pa storage modulus for the 
following in vitro and in vivo investigations. 
3.4 ADSCs’ behaviors in HP-PEG/HA-SH hydrogels  
Stem cell therapy has been proven to be safe and efficient by many researchers and 
preclinical studies due to their unique features, such as self-renewal and differentiation 
potential.[3,43,44] Among various types of stem cells, ADSCs are of great interest as 
they can be easily isolated from the abundant source of fat tissue, and possess 
characteristics resembling those of mesenchymal stem cells. Besides, ADSCs have the 
potential to promote tissue regeneration through secreting essential factors to stimulate 
angiogenesis and re-epithelialization.[3,45] However, the maintenance of cell viability 
and stemness is an urgent issue to be solved under the hostile environment of DFUs. We 
then further detected the ADSCs’ behaviors (self-renewal and secretion ability) in this 
hydrogel system. The expression of Oct4, Sox2, and Nanog, which are key regulators 
for maintenance of self-renewal and multipotency of ADSCs,[7,46] was verified by 
immunological staining method (Figure 4A). Most of the ADSCs are showing 
positively stained Oct4, Sox2, or Nanog after 2, 5, and 7 days seeding in the hydrogel. 
We also assessed the differentiation status of the encapsulated ADSCs with or without 
specific induction media. After induction, ADSCs are directed to differentiate into 
adipogenic, osteogenic, and chondrogenic lineages, verified by the staining of oil red O, 
safranin-O, and alizarin red staining, respectively (Figure 4B), while the ADSCs, 
without induction, showed no sign of differentiation. These data demonstrated that 
ADSCs maintained their stemness well even in the hydrogel. The protein level of 
pro-angiogenic growth factors was detected on conditioned media from hydrogel and 
plated culture conditions. It can be noted that the protein levels of PIGF, VEGF, and 
TGF-β were increased from day 1 to day 7 in both conditioned media (Figure 4C, D, 
and E). PIGF expression was found to be significantly increased at day 7 in hydrogel 
cultured ADSCs compared to those cultured in standard conditions. VEGF and TGF-β 
expression was found to significantly increased at day 1 and day 4. The ability of 
maintaining the multi-potency and secretion capacity of wound healing associated 
growth factors of these encapsulated ADSCs in the HP-PEG-based hydrogel exhibits 
potential therapeutic value in regenerative medicine, indicating the possibility of the 
combination therapy in promoting wound healing. 
3.5 HP-PEG/HA-SH/ADSCs promotes humanized diabetic wound healing process  
To test the efficiency of the injectable HP-PEG/HA-SH hydrogel in promoting wound 
healing, a humanized excisional wound model, which can better mimic human skin 
wound repair mechanisms[47], was developed in the Streptozotocin induced diabetic 
SD rats. To validate our hypothesis that the HP-PEG/HA-SH/ADSCs system can 
accelerate diabetic wound healing, no-treatment (blank), and treatment with 
INTRASITE◊GEL (a commercially available product from Smith & Nephew (S&N)), 
direct local injection of ADSCs, and injectable HP-PEG/HA-SH hydrogel (blank 
hydrogel) were used as controls to bolster the comparison. The treatment process by 
injectable hydrogel was recorded as Supplementary movie 1. Wound closure rate (%) 
was defined as: (origin wound area - residual wound area at day ‘X’) / origin wound 
area × 100%. In the present study, the wounds treated with HP-PEG/HA-SH/ADSCs 
showed significantly accelerated wound closure rate than no treatment wounds (1.9- 
and 1.4-fold faster) and cell only treated wounds (1.3- and 1.3-fold faster) at days 11 
and 21 post-wounding (Figure 5A and B). H&E staining sections show that, 
HP-PEG/HA-SH/ADSCs treated wounds yielded an accelerated healing rate compared 
with the no treatment wounds, as proved by the formation of a thicker granular tissue 
(Figure 5C). We then performed Masson’s trichrome assay (Figure 5D) to further 
understand the dermis deposition which provides the initial support for cell migration. 
HP-PEG/HA-SH/ADSCs hydrogel treated wounds regenerated a much thicker dermis 
than no treatment wounds (95.2% ± 1.7 vs 42.2% ± 3.4, p<0.01) and cell only treated 
wounds (95.2% ± 1.7 vs 75.5% ± 7.3, p<0.01) (Figure 5E). Additionally, collagen 
remodeling in the ADSCs alone and HP-PEG/HA-SH/ADSCs hydrogel treated wounds 
is more homogenous than other groups. 
The prolonged inflammation, reduced vascular formation, and non-migratory 
epidermis in diabetic wound beds are considered to be essential factors in impaired and 
delayed diabetic wound healing. To further study the mechanism behind the accelerated 
healing, we performed immunohistochemistry or immunofluorescence assays for the 
wound tissues. Inflammatory factors (CD11b, TNF α, IL-1β) expression were 
significantly inhibited at days 11 and 21 in HP-PEG/HA-SH/ADSCs hydrogel treated 
wounds, indicating the prolonged inflammatory phase is reversed (Figure 6A, Figure 
S12 and Figure 7). To study the angiogenesis behaviours during the healing, protein 
expression of key factors related to vascular development (VEGF, CD31, and α-SMA) 
were detected. The number of CD31 and α-SMA positive stained vessels of each wound 
was counted (Figure 6B and Figure 6C), respectively. CD31+ and α-SMA+ vessel 
densities were significantly higher in HP-PEG/HA-SH/ADSCs hydrogel treated 
wounds at day 21. VEGF expression also indicated a higher level in 
HP-PEG/HA-SH/ADSCs hydrogel treated wounds demonstrating a positive effect for 
angiogenesis (Figure 6D). Enhanced re-epithelialization rate was evidenced by the 
gap-junctional connections of keratinocytes layers (Figure 6E and Figure S13) at day 
21. There are also significant differences between cell only and hydrogel/cell treated 
wounds, such as increased neodermis thickness, inhibited inflammatory factors 
expression, enhanced CD31 and VEGF expression and re-epithelialization at 21 days 
from Figure 6. Based on the histological assays, the HP-PEG/HA-SH/ADSCs system 
presented significant advantages for diabetic wound healing, including prevention of 
persistent inflammation, promotion of vasculogenesis, and re-epithelialization 
compared to the wounds without treatment.  
4. Conclusion 
In this report, we have described the development of an new injectable hydrogel 
platform as a stem cell delivery and retention system. The in situ RAFT 
polymerization of PEGDA using DS as a RAFT agent precursor endows the resultant 
hyperbranched PEG polymers good biocompatibility and abundant pendent acrylate 
groups, which can be utilized to form an injectable hydrogel with a rapid gelation rate 
and a tunable mechanical property. The HP-PEG/HA-SH hydrogels also demonstrated 
non-swelling and antifouling properties, as well as well-retained stem cell properties 
in vitro. Furthermore, this versatile hydrogel system encapsulated with ADSCs 
exhibited an accelerated diabetic wound healing process through inhibiting 
inflammation, promoting angiogenesis and re-epithelialization.  
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 Figures and figure caption 
 
Figure 1. Schematic concepts of the generation and application of injectable 
HP-PEG-based hydrogel. Scheme illustrates the synthesis of the HP-PEG polymers 
by in situ RAFT polymerization using AIBN as the initiator and DS as the precursor 
of RAFT agent. The hydrogel is in situ formed via thiol-ene reaction by mixing 
HP-PEG with HA-SH. ADSCs are encapsulated in the hydrogel and the hydrogel 
system is applied onto a humanized diabetic wound model.  
 
  
Figure 2. Kinetic plots for in situ RAFT polymerization of PEGDA. A-D, 
Dependence of the molecular weight (Mw) and polydispersity index (PDI) on the 
monomer conversion for the in situ RAFT polymerization. A, entry 3. B, entry 4. C, 
entry 5. D, entry 6. E, Conversion of HP-PEG versus reaction time. The monomer 
conversion increasing with reaction time; F, Zoom in areas of 1H-NMR spectrums of 
purified polymer samples taken from entry 4. 
 
  
 
Figure 2. Properties of HP-PEG/HA-SH hydrogels. A, Gelation time of 
HP-PEG/HA-SH hydrogels. B, Gelation process of HP-PEG1/HA-SH hydrogel 
characterized by rheometer. C, Storage modulus of injectable HP-PEG/HA-SH 
hydrogels at different concentrations D, Swelling behaviour of injectable 
HP-PEG/HA-SH hydrogels obtained by incubating in PBS at 37 oC. After 60 days, the 
hydrogels showed shapeless, loose property and finally disappeared at approximately 
75 days. E, Evaluation of protein adsorption on hydrogels determined by Micro BCA 
protein assay. 
 
 
  
Figure 4. Stemness and secretion of the ADSCs in HP-PEG/HA-SH hydrogel. A, 
Immunological staining images for Oct4, Sox2, and Nanog of ADSCs encapsulated in 
the hydrogels after 2, 5, and 7 days post-encapsulation. B, Differentiation status of 
ADSCs in the hydrogel into adipogenic, osteogenic, and chondrogenic lineages using 
oil red O, Alizarin red, and safranin-O staining. C, D, and E, Protein levels of PIGF, 
VEGF, and TNF-β in conditioned media from ADSCs cultured in hydrogels compared 
to those plated under standard conditions. Scale bar, A and B, 100 μm. *, p<0.05; **, 
p<0.01. 
 
 
  
Figure 5. Treatments with humanized excisional wound model in diabetic rats. A, 
Representative images of wounds during 21-day in vivo experiments. B, Quantification 
of wound closure rate (%) over 21-day period. C, H&E staining of wounds at days 11 
and 21 post-wounding. The sites of initial tissue injury are indicated by arrows. 
Magnifications of the corresponding boxed areas at day 21 are shown in the right, 
respectively. HS and Gr are represented as healthy skin and granulation matrix. D, 
Masson’s trichrome staining of full-length wound sections at 21 days post-wounding. 
Magnifications of the corresponding boxed areas are shown in the right, respectively. 
E, Percentages of newly-formed tissue thickness at 21 days post-wounding. Injectable 
HP-PEG/HA-SH/ADSCs hydrogel treated wounds show significantly promoted 
healing than the no-treatment wounds (n = 8 for each condition). Histological sections 
show a more homogenous morphology of tissues and thicker collagen deposition in the 
injectable HP-PEG/HA-SH/ADSCs hydrogel treated wounds. Scale bars: C and D, 1 
mm; (c1)-(c10) and (d1)-(d10), 100 μm. *, p<0.05; **, p<0.01. 
 
 
  
Figure 6. Quantitative analysis based on the immunohistochemical staining slides. A, 
Quantification analysis of the positive stained inflammatory cytokines which indicate 
total cellular infiltration in the wound areas as well as immune response in the 
surrounding tissue. Less secretion of inflammatory factors is observed in injectable 
HP-PEG/HA-SH/ADSCs hydrogel treated wounds. B and C, Quantifications analysis 
of blood vessels based on CD31 and α-SMA positive stained vasculature. CD31 is 
located on the surface of endothelial cells; α-SMA is localized on smooth muscle cells; 
both are known markers for vascular networks. The injectable hydrogels treated group 
exhibits significantly higher vessel density than no-treatment group at 11 and 21 days 
post-wounding. D, Intensity of VEGF expression in each experimental group. More 
secretion of VEGF is seen in HP-PEG/HA-SH/ADSCs hydrogel treated wounds. E, 
Quantification analysis of re-epithelialization rate at days 11 and 21 post-wounding. 
There is a much faster re-epithelialization rate in injectable HP-PEG/HA-SH/ADSCs 
hydrogel than that in no-treatment group. *, p<0.05; **, p<0.01. 
 
  
Figure 7. Immunofluorescent staining of wound sections in diabetic wound tissues. A, 
Representative immunofluorescent images of tissue sections at 11 days 
post-wounding for TNF-α (green) and DAPI staining for nuclei (blue). B, 
Representative immunofluorescent images of tissue sections for CD31 (red), α-SMA 
(green), and DAPI (for cell nuclei, blue) stained images (21 days post-wounding). 
Yellow triangles represent CD31+/α-SMA- vessels, and yellow arrows represent 
CD31+/α-SMA+ vessels. Scale bar: 100 μm. 
